More FLML
Saturday, August 25th, 2007 by Mark [+/-] show/hide this excerptFLML’s price has taken a nose-dive recently. There are some valid reasons, though.
Their only profit generating drug is Coreg CR, a heart failure compound marketed by GlaxoSmithKline. Unfortunately for Flamel, Glaxo has been in some serious trouble over its Avandia medication, causing them to divert salespeople who should have been selling Coreg CR [...]
